老虎证券

BRIEF-Sanofi's AERIFY-1 Met Primary Endpoint, AERIFY-2 Did Not

Reuters
05-30
BRIEF-<a href="https://laohu8.com/S/GCVRZ">Sanofi</a>'s AERIFY-1 Met Primary Endpoint, AERIFY-2 Did Not

May 30 (Reuters) - Sanofi SA SASY.PA:

  • PRESS RELEASE: ITEPEKIMAB MET THE PRIMARY ENDPOINT IN ONE OF TWO COPD PHASE 3 STUDIES

  • SANOFI SA - AERIFY-1 STUDY SHOWS SIGNIFICANT REDUCTION IN COPD EXACERBATIONS

  • SANOFI - ITEPEKIMAB WAS GENERALLY WELL TOLERATED IN BOTH AERIFY-1 AND AERIFY-2

  • SANOFI SA - AERIFY-2 STUDY DOES NOT MEET PRIMARY ENDPOINT

  • SANOFI SA - ITEPEKIMAB GENERALLY WELL TOLERATED IN BOTH STUDIES

  • SANOFI - SANOFI AND REGENERON ARE ASSESSING DATA AND WILL DISCUSS WITH REGULATORY AUTHORITIES TO EVALUATE NEXT STEPS

Source text: ID:nGNX1ppZlG

Further company coverage: SASY.PA

(Gdansk Newsroom)

((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10